Enjoy complimentary customisation on priority with our Enterprise License!
Some of the key findings from our MEK inhibitors market forecast report are summarized below
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The use of protein biomarkers in the diagnosis of NSCLC will be one of the critical MEK inhibitors market trends driving market growth. The level of protein biomarkers such as pro-gastrin-releasing peptide (ProGRP), C-reactive protein (CRP), carcinoembryonic antigen (CEA), NSE, cytokeratin-19 fragment 21-1 (CYFRA21-1), squamous-cell carcinoma antigen (SCCA), and trehalose-6-phosphate synthase (TPS) is high among patients with NSCLC. The treatment of NSCLC involves protein biomarker testing of tumor samples followed by therapies in the first-line testing. The use of protein biomarkers is preferred for the diagnosis of NSCLC because of its high diagnostic efficacy. The use of predictive protein biomarkers also minimizes the treatment cost and adverse effects associated with the treatment. MEK inhibitors are generally the most preferred types of drugs for the treatment of NSCLC associated with BRAF mutation. The advances in protein biomarker testing for the diagnosis of NSCLC will have a positive impact on the growth of the MEK inhibitors market.
The high target affinity and specificity of MEK inhibitors will also contribute to the growth of the market. Approved therapies for the treatment of advanced or metastatic carcinomas, such as melanoma and NSCLC, have low patient adherence because of their several side effects. However, MEK inhibitors have emerged as one of the ideal solutions for cancer treatments because of their high efficacy in oncology applications. MEK inhibitors exhibit higher efficacy than conventional treatments as they act directly on the target. MEK inhibitors also help in decreasing the growth of tumors in people with metastatic melanoma by hindering the activity of MEK and BRAF kinases. The promising results demonstrated by MEK inhibitors in oncology have encouraged researchers to expand its applications to other invasive cancer indications, such as colorectal cancer. The high target affinity and specificity of MEK inhibitors will boost its popularity among end-users and fuel the growth of the market at a CAGR of over 8% during the forecast period.
The global MEK inhibitors market is concentrated. To help clients improve their market position, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this MEK inhibitors market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading MEK inhibitors companies, including:
The MEKINIST segment will account for the highest MEK inhibitors market share. The increasing sale of MEKINIST because of the expansion of research indications focusing on new patient pools will be one of the significant factors driving the growth of the MEK inhibitors market in this segment. This market research report provides an accurate prediction of the contribution of all the segments to the growth of the MEK inhibitors market size.
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest MEK inhibitors market share throughout the forecast period. The rising prevalence of several cancer indications and the increasing sales of approved MEK inhibitors are responsible for MEK inhibitors market growth in this segment.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.